Lineage Cell Therapeutics
LCTX
LCTX
80 hedge funds and large institutions have $113M invested in Lineage Cell Therapeutics in 2015 Q2 according to their latest regulatory filings, with 17 funds opening new positions, 27 increasing their positions, 19 reducing their positions, and 5 closing their positions.
New
Increased
Maintained
Reduced
Closed
more call options, than puts
Call options by funds: $ | Put options by funds: $
more first-time investments, than exits
New positions opened: | Existing positions closed:
more repeat investments, than reductions
Existing positions increased: | Existing positions reduced:
more funds holding
Funds holding: →
0.72% more ownership
Funds ownership: 45.54% → 46.25% (+0.72%)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
26% less capital invested
Capital invested by funds: $152M → $113M (-$38.9M)
Holders
80
Holding in Top 10
1
Calls
$3.08M
Puts
$507K
Top Buyers
| 1 | +$2.15M | |
| 2 | +$940K | |
| 3 | +$599K | |
| 4 |
OAM
Oxford Asset Management
Oxford,
United Kingdom
|
+$411K |
| 5 |
VKH
Virtu KCG Holdings
New York
|
+$291K |
Top Sellers
| 1 | -$3.44M | |
| 2 | -$683K | |
| 3 | -$471K | |
| 4 |
Citadel Advisors
Miami,
Florida
|
-$276K |
| 5 |
MLICM
Metropolitan Life Insurance Company (MetLife)
New York
|
-$223K |